Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 123

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 123
---
 at a purchase price of $0.20 per common share and $0.1999 per pre-funded warrant for aggregate gross proceeds of approximately $0.788 million. On November 17, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 3,991,768 common shares, and (ii) pre-funded warrants to purchase up to 1,518,000 common shares, in a registered direct offering at a purchase price of $0.25 per common share and $0.2499 per pre-funded warrant for aggregate gross proceeds of approximately $1.377 million. On November 19, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of 10,925,000 common shares, at a purchase price of $0.20 per common share for aggregate gross proceeds of approximately $2.185 million. On November 26, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 7,944,868 common shares, and (ii) pre-funded warrants to purchase up to 2,865,960 common shares, in a registered direct offering at a purchase price of $0.12 per common share and $0.1199 per pre-funded warrant for aggregate gross proceeds of approximately $1.294 million. On December 3, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of 16,000,000 common shares, at a purchase price of $0.10 per common share for aggregate gross proceeds of approximately $1.6 million. As of December 3, investors from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894,769 common shares, including warrants to purchase 1,881,250 common shares on a cashless basis. As a result, we issued an aggregate of 2,090,987 common shares and received aggregate gross proceeds of approximately $183,000 from such exercises. We have financed our operations for the last year primarily from our issuance of Common Shares and warrants. 76 Nine Months Ended July 31, 2025 Compared to Nine Months Ended July 31, 2024 The table below shows a summary of our cashflows for the periods indicated:

| Nine Months Ended July 31,                |     |                  |        |   |     |      |        |   |
|                                           |